PROJECT SUMMARY/ABSTRACT The goal of the Sidney Kimmel Comprehensive Cancer Center Hematologic Malignancies and Bone Marrow Transplantation Program is to improve the understanding and treatment of hematologic malignancies and related disorders. The Program is focused on three scientific aims that cross disease boundaries and bridge laboratory and clinical efforts: (1) targeting genetic and epigenetic alterations in hematologic malignancies, (2) studying normal and neoplastic lymphohematopoiesis, and (3) improving bone marrow transplantation (BMT) outcomes. These thematic investigations extend from basic observations in the laboratory to clinical trials and from clinical observations back to laboratory investigation. Led by Richard F. Ambinder, M.D., Ph.D., and Richard J. Jones, M.D., the Program consists of 29 Program full Members, 15 of whom have peer-reviewed funding, and an additional eleven Associate Members, including six with active K awards during this last funding period. The Program has members with appointments in five departments across two schools at Johns Hopkins. The total direct cancer-relevant peer-reviewed funding is $4.4 million, with $1.7 million from the National Cancer Institute, with two new investigators having received their first R01s in the last year. The total number of publications by Program members since last review is 508, of which 148 (29.1%) are Intra-Programmatic, 91 (17.9%) are Inter-Programmatic and 325 (64.0%) have external collaborations. Of these publications, 25% are in journals with impact factors >10 and 5.3% in journals with impact factors >25. Since the last review, the Program has continued to be an international leader in the development of novel new treatments for hematologic malignancies and related disorders. In additional to overseeing the interdisciplinary/thematic focus of the faculty members in the Program, Program leadership is also responsible for prioritizing resources and ensuring that interactions are synergistic. Success in these endeavors has been recognized by funding of several multicomponent grants: continued funding for a Program Project Grant in BMT, the BMT Clinical Trials Network (CTN) Core Center Grant and the AIDs Malignancy Consortium, as well as new funding of a myeloma Stand Up to Cancer grant, a Moonshot grant to study BMT in brain cancers, and a multi-institutional grant to study CHIP and myelodysplastic syndromes in sickle cell disease. In addition, the Program has played a vigorous role in the development and execution of relevant clinical trials, including national cooperative group endeavors of ECOG-ACRIN, COG, NCTN, ETCTN, the BMT CTN and the AIDS Malignancy Consortium, with many examples of therapeutic strategies taken from the laboratory, through early clinical testing and into national multi-institutional trials.